Home / Drug development / CMC and beyond / GMP starting materials
Smarter GMP starting materials
We provide GMP manufacturing services for starting materials and advanced intermediates that enable Drug Substance preparation for GLP toxicology and clinical development.
With multi-purpose facilities across Europe and North America and batch manufacturing capabilities from 10 L to 1,000 L, we combine pharmaceutical process development, solid-state chemistry and regulatory-aligned quality systems to deliver reliable, phase-appropriate materials.
Every project is managed with transparency and precision to reduce risk, ensure supply continuity and keep your molecule on track toward CMC development and IND readiness.
Our approach includes:
- Route design and scale-up – We design and optimise chemistry from gram to multi-kilogram scale, applying expertise across chiral chemistry, biocatalysis, chemo-catalytic and continuous flow technologies to improve efficiency and reproducibility.
- Flexible, phase-appropriate solutions – Approaches tailored to your development stage – from targeted services to fully integrated CMC support – to ensure regulatory alignment, quality and steady progress toward IND.
- Collaborative, open communication – Direct access to expert chemists, proactive problem-solving and clear data sharing keep your program informed, nimble and moving forward with confidence.
Solving problems in GMP starting materials
25+ years of experience
Supporting complex synthesis with deep process knowledge and phase-appropriate GMP manufacturing that ensures dependable delivery and development-ready quality.
80% repeat clients
Chosen by global biotech and pharma partners for our scientific insight, clear communication, and the consistency that builds lasting relationships
Integrated chemistry, manufacturing and controls
Beyond GMP starting materials, we provide fully integrated CMC development – from solid-state R&D and Drug Substance scale-up (40–1,000L) to GMP Drug Product manufacturing.
This connected approach delivers consistency, reduces transfer risk and gives you a clear, reliable path from early development through IND submission.
What do our partners say?
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
Your discovery and development partner that sees beyond
Symeres support small-molecule programs from discovery through IND with openness, agility and scientific depth. Our connected teams in Europe and North America provide medicinal chemistry, computational chemistry, synthetic chemistry, and specialty chemistry services integrated with biology, ADME-tox, and CMC development.
We share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous. Projects can run as standalone studies or as coordinated, multi-disciplinary programs.
Resources we think you'll love
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Connect with our GMP manufacturing experts
See how we can support the discovery and development of your next breakthrough.